Comparative Risks of Initial Aortic Events Associated With Genetic Thoracic Aortic Disease.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
30 08 2022
Historique:
received: 11 03 2022
revised: 26 04 2022
accepted: 20 05 2022
entrez: 25 8 2022
pubmed: 26 8 2022
medline: 30 8 2022
Statut: ppublish

Résumé

Pathogenic variants in 11 genes predispose individuals to heritable thoracic aortic disease (HTAD), but limited data are available to stratify the risk for aortic events associated with these genes. This study sought to compare the risk of first aortic event, specifically thoracic aortic aneurysm surgery or an aortic dissection, among 7 HTAD genes and variant types within each gene. A retrospective cohort of probands and relatives with rare variants in 7 genes for HTAD (n = 1,028) was assessed for the risk of first aortic events based on the gene altered, pathogenic variant type, sex, proband status, and location of recruitment. Significant differences in aortic event risk were identified among the smooth muscle contraction genes (ACTA2, MYLK, and PRKG1; P = 0.002) and among the genes for Loeys-Dietz syndrome, which encode proteins in the transforming growth factor (TGF)-β pathway (SMAD3, TGFB2, TGFBR1, and TGFBR2;P < 0.0001). Cumulative incidence of type A aortic dissection was higher than elective aneurysm surgery in patients with variants in ACTA2, MYLK, PRKG1, and SMAD3; in contrast, patients with TGFBR2 variants had lower cumulative incidence of type A aortic dissection than elective aneurysm surgery. Cumulative incidence of type B aortic dissection was higher for ACTA2, PRKG1, and TGFBR2 than other genes. After adjusting for proband status, sex, and recruitment location, specific variants in ACTA2 and TGFBR2 were associated with substantially higher risk of aortic event with childhood onset. Gene- and variant-specific data on aortic events in individuals with HTAD support personalized aortic surveillance and clinical management.

Sections du résumé

BACKGROUND
Pathogenic variants in 11 genes predispose individuals to heritable thoracic aortic disease (HTAD), but limited data are available to stratify the risk for aortic events associated with these genes.
OBJECTIVES
This study sought to compare the risk of first aortic event, specifically thoracic aortic aneurysm surgery or an aortic dissection, among 7 HTAD genes and variant types within each gene.
METHODS
A retrospective cohort of probands and relatives with rare variants in 7 genes for HTAD (n = 1,028) was assessed for the risk of first aortic events based on the gene altered, pathogenic variant type, sex, proband status, and location of recruitment.
RESULTS
Significant differences in aortic event risk were identified among the smooth muscle contraction genes (ACTA2, MYLK, and PRKG1; P = 0.002) and among the genes for Loeys-Dietz syndrome, which encode proteins in the transforming growth factor (TGF)-β pathway (SMAD3, TGFB2, TGFBR1, and TGFBR2;P < 0.0001). Cumulative incidence of type A aortic dissection was higher than elective aneurysm surgery in patients with variants in ACTA2, MYLK, PRKG1, and SMAD3; in contrast, patients with TGFBR2 variants had lower cumulative incidence of type A aortic dissection than elective aneurysm surgery. Cumulative incidence of type B aortic dissection was higher for ACTA2, PRKG1, and TGFBR2 than other genes. After adjusting for proband status, sex, and recruitment location, specific variants in ACTA2 and TGFBR2 were associated with substantially higher risk of aortic event with childhood onset.
CONCLUSIONS
Gene- and variant-specific data on aortic events in individuals with HTAD support personalized aortic surveillance and clinical management.

Identifiants

pubmed: 36007983
pii: S0735-1097(22)05426-2
doi: 10.1016/j.jacc.2022.05.054
pii:
doi:

Substances chimiques

Receptor, Transforming Growth Factor-beta Type II EC 2.7.11.30

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

857-869

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL109942
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL127266
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures These studies were funded by the National Institutes of Health (NIH) (NIH R01HL109942 to Dr Milewicz DMM and K23HL127266 to Dr Morris), Genetic Aortic Disorders Association Canada, Temerty Family Foundation, and the John Ritter Foundation. Dr LeMaire serves as a consultant for Terumo Aortic and Cerus; and serves as a principal investigator for clinical studies sponsored by Terumo Aortic and CytoSorbents. Dr Morris is on the scientific advisory board for vascular Ehlers Danlos syndrome clinical trial for Aytu Biopharma. Dr Regalado is an employee and shareholder of Invitae. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Ellen S Regalado (ES)

Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, USA.

Shaine A Morris (SA)

Division of Pediatric Cardiology, Baylor College of Medicine, Houston, Texas, USA.

Alan C Braverman (AC)

Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.

Ellen M Hostetler (EM)

Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, USA.

Julie De Backer (J)

Department of Cardiology and Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium; European Reference Network for Rare Multisystemic Vascular Disease (VASCERN), Heritable Thoracic Aortic Disease Working Group.

Ruosha Li (R)

Department of Biostatistics and Data Science, School of Public Health, UTHealth, Houston, Texas, USA.

Reed E Pyeritz (RE)

Departments of Medicine and Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Anji T Yetman (AT)

Division of Pediatric Cardiology, Children's Hospital & Medical Center, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Elena Cervi (E)

Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.

Sherene Shalhub (S)

Department of Vascular Surgery, University of Washington, Seattle, Washington, USA.

Richmond Jeremy (R)

Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Scott LeMaire (S)

Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA.

Maral Ouzounian (M)

Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada.

Arturo Evangelista (A)

European Reference Network for Rare Multisystemic Vascular Disease (VASCERN), Heritable Thoracic Aortic Disease Working Group; Department of Cardiology, Hospital Vall d'Hebron, Vall d'Hebron Research Institute, CIBER-CV, Barcelona, Spain.

Catherine Boileau (C)

European Reference Network for Rare Multisystemic Vascular Disease (VASCERN), Heritable Thoracic Aortic Disease Working Group; CRMR Syndrome de Marfan et apparentés, Department of Cardiology, AP-HP, INSERM U1148, Hopital Bichat, Université de Paris, Paris, France.

Guillaume Jondeau (G)

European Reference Network for Rare Multisystemic Vascular Disease (VASCERN), Heritable Thoracic Aortic Disease Working Group; CRMR Syndrome de Marfan et apparentés, Department of Cardiology, AP-HP, INSERM U1148, Hopital Bichat, Université de Paris, Paris, France.

Dianna M Milewicz (DM)

Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, USA. Electronic address: Dianna.M.Milewicz@uth.tmc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH